ZYME vs ADPT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

ZYME

48.2
AI Score
VS
ZYME Wins

ADPT

40.4
AI Score

Investment Advisor Scores

ZYME

48score
Recommendation
HOLD

ADPT

40score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME ADPT Winner
Revenue 263.46M 226.33M ZYME
Net Income 84.52M -56.95M ZYME
Net Margin 32.1% -25.2% ZYME
Operating Income 88.30M -35.43M ZYME
ROE 32.7% -32.3% ZYME
ROA 7.2% -8.3% ZYME
Total Assets 1.18B 683.12M ZYME
Cash 100.46M 75.61M ZYME
Current Ratio 3.30 3.97 ADPT
Free Cash Flow -101.99M -10.24M ADPT

Relative Price Performance (Last 90 Days)

ZYME 1M: +10.3% · 3M: +8.7% ADPT 1M: +15.3% · 3M: +19.4%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $27.32

ADPT

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 60

RSI (14): 60.0 · Price: $29.54

Fundamentals Snapshot

Metric ZYME ADPT
Market Cap — —
Forward P/E 23.9 -1446.4
Trailing P/E 59.4 —
Revenue (TTM) — —
Revenue Growth 8.3% -0.1%
Gross Margin 0.5% 0.5%
Operating Margin 0.7% 0.0%
EPS 0.53 -0.45
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.